Gt biopharma announces the appointments of gregory berk, m.d. to chief medical officer and jeffrey s.

Beverly hills, calif., april 26, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike™ protein biologic technology platform, today announced the appointment of gregory berk, m.d.
GTBP Ratings Summary
GTBP Quant Ranking